Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
CSF isoprostane levels are a biomarker of oxidative stress in multiple sclerosis.
Endogenous and synthetic MMP inhibitors in CNS physiopathology.
Treating prolactinoma can prevent autoimmune diseases.
TRANSGLUTAMINASE 2 IS INVOLVED IN HOMOCYSTEINE-INDUCED ACTIVATION OF HUMAN THP-1 MONOCYTES.
Quantitative sensory and motor measures detect change over time and correlate with walking speed in individuals with multiple sclerosis.
[Vaccines and central nervous system demyelinating diseases: New studies on the internet –not just new rumors].
Commentary on Pique et al.'s paper entitled: Peripheral late reactivation of a previously typical monofocal Balo's concentric sclerosis lesion.
Region and dynamic specificities of adult neural stem cells and oligodendrocyte precursors in myelin regeneration in the mouse brain.
Developmental cuprizone exposure impairs oligodendrocyte lineages differentially in cortical and white matter tissues and suppresses glutamatergic neurogenesis signals and synaptic plasticity in the hippocampal dentate gyrus of rats.
Placebo controlled trials in neuromyelitis optica are needed and ethical.
Polyarteritis nodosa with central nervous system involvement mimicking relapsing-remitting multiple sclerosis.
[Diagnosis and differential diagnosis of demyelinating optic neuropathy in multiple sclerosis.]
Clinical impact of early brain atrophy in clinically isolated syndromes.
EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2.
Cost effectiveness of Sativex for spasticity in multiple sclerosis.
Assessing relapse in multiple sclerosis questionnaire: results of a pilot study.
Robot Therapy Tipping Point: Caveats for Post hoc Speculation.
Persistent visual impairment in multiple sclerosis: prevalence, mechanisms and resulting disability.
The Different Clinical Effects of Anti-BLyS, Anti-APRIL and Anti-CD20 Antibodies Point at a Critical Pathogenic Role of γ-Herpesvirus Infected B Cells in the Marmoset EAE Model.
Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis.
Upregulation of ciliary neurotrophic factor in astrocytes by aspirin: Implications for remyelination in multiple sclerosis.
The Disease-Ameliorating Function of Autoregulatory CD8 T Cells Is Mediated by Targeting of Encephalitogenic CD4 T Cells in Experimental Autoimmune Encephalomyelitis.
Feasibility of Cell Therapy in Multiple Sclerosis: A Systematic Review of 83 Studies.
A subtraction pipeline for automatic detection of new appearing multiple sclerosis lesions in longitudinal studies.
Outcome measures in multiple sclerosis.
Pages
« first
‹ previous
…
544
545
546
547
548
549
550
551
552
…
next ›
last »